anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a medicinal preparation, particularly to a large capacity injection prepared from sodium ferulate. Every 1 ml of physic liquor in the injection contains 0.1 mg to 6.0 mg of sodium ferulate; the physic liquor is filled into an infusion bottle and can be directly administered for intravenous injection; the physic liquor can be a water solution of sodium ferulate; or furthermore, isotonic agents, antioxidants, etc. can be added to the physic liquor. The preparation method of the large capacity sodium ferulate injection comprises: weighing and taking a definite quantity of sodium ferulate and selectively added isotonic agents, antioxidants, etc.; adding water or other proper solvents to prepare physic liquor, wherein every 1 ml of the physic liquor contains 0.1 mg to 6.0 mg of sodium ferulate; regulating the pH value of the prepared physic liquor; filtering the physic liquor through a 0.45 mum to 0.22 mum microporous filtering film until the physic liquor is clear; filling the physic liquor into bottles and introducing nitrogen (N2); rolling covers and hot pressing for sterilization for a predetermined period of time; obtaining finished products of sodium ferulate large capacity injections. The sodium ferulate large capacity injection of the present invention has the advantages of safe and convenient use; the present invention is especially suitable for the first aid for patients with acute and severe diseases and meets the requirement of medical treatment.
Belonging to the field of medical technologies, the invention provides a method for preparation of selaginellin M with a content of over 95% from Chinese medicine selaginella. The compound has a structure shown as formula (I). The selaginellin M in the invention adopts the dry herb raw material of Selaginellaceae plant Selaginella tamariscina (Beauv.) Spring or Selaginella pulvinata (Hook.et Grev.) Maxim. as the starting raw materials, an organic solvent and/or water are/is employed for extraction, and a macroporous resin adsorption and Sephadex LH-20 adsorption combined separation method is used for separating, thus obtaining the selaginellin M. The method provided by the invention has the advantages of simple process operation, good repeatability, high yield and suitability for industrial production, and the product has high purity, and the content is detected to be over 95% by HPLC method. (formula I as shown in the description).
BACKGROUND: Tar is the main toxic of cigarettes, and its effect on atherosclerosis progression and the underlying mechanisms remain largely unknown. Vascular smooth muscle cells (VSMCs) play a key role in atherogenesis and plaque vulnerability. The present study sought to investigate the mechanism of atherosclerosis progression through tar-induced VSMC necroptosis, a recently described form of necrosis.
METHODS: The effect of tar on atherosclerosis progression and VSMC necroptosis was examined in ApoE-/- mice and cultured VSMCs. The role of necroptosis in tar-induced plaque development was evaluated in RIPK3-deletion mice (ApoE-/-RIPK3-/-). The key proteins of necroptosis in carotid plaques of smokers and non-smokers were also examined. Quantitative proteomics of mice aortas was conducted to further investigate the underlying mechanism. Pharmacological approaches were then applied to modulate the expression of targets to verify the regulatory process of tar-induced necroptosis.
RESULTS: Tar administration led to increased atherosclerotic plaque area and reduced collagen and VSMCs in ApoE-/- mice. The expression of RIPK1、RIPK3、and MLKL in VSMCs of plaques were all increased in tar-exposed mice and smokers. RIPK3 deletion protected against VSMC loss and plaque progression stimulated by tar. In mechanistic studies, quantitative proteomics analysis of ApoE-/- mice aortas suggested that tar triggered endoplasmic reticulum (ER) stress. PERK-eIF2α-CHOP axis was activated in tar-treated VSMCs and atherosclerotic plaque. Inhibition of ER stress using 4PBA significantly reduced plaque progression and VSMC necroptosis. Further study revealed that ER stress resulted in calcium (Ca2+) release into mitochondria and cytoplasm. Elevated Ca2+ levels lead to mitochondrial dysfunction and excessive reactive oxygen species (ROS) production, which consequently promote RIPK3-dependent necroptosis. In addition, Ca2+/calmodulin-dependent protein kinase II (CaMKII) activated by cytosolic Ca2+ overload binds to RIPK3, accounting for necroptosis.
CONCLUSION: The findings revealed that cigarette tar promoted atherosclerosis progression by inducing RIPK3-dependent VSMC necroptosis and identified novel avenues of ER stress and Ca2+ overload.
Mothers and fathers will be asked for permission to follow the child's health information from national registers until the age of 15 years. Approximately 300 children will be recruited to PEPPI-offspring follow up study (including also PCOS offspring).
Participants randomized to I-MBCT (Mindfulness-Based Cognitive Therapy) receive 12 weekly 60- minute sessions of I-MBCT according to the protocol of Segal et al. (2002), integrated with the "theme, rationale, intention and practice" skills (TRIP) protocol (Woods et al. 2016, 2019). The original MBCT protocol, created for eight group sessions lasting two hours, is adapted to twelve individual sessions.
Various scoring systems have been developed to predict outcomes in patients with non-variceal upper gastrointestinal bleeding (NVUGIB). However, their accuracy remains unclear. This study aimed to compare and validate the predictive performance of several established scoring systems in patients with NVUGIB: Glasgow-Blatchford score (GBS) and the age, blood tests, and comorbidities (ABC), mental status-anesthesiologist score-pulse-albumin-systolic blood pressure-hemoglobin (MAP(ASH)), Japanese, and Charlson comorbidity index-in-hospital onset-albumin-mental status-Eastern Cooperative Oncology Group performance status-steroids (CHAMPS) scores. We retrospectively reviewed the records of 1,241 patients who presented to the emergency department with NVUGIB and subsequently required hospitalization. Each scoring system was evaluated for its ability to predict in-hospital mortality, rebleeding, and the need for radiological or surgical intervention. The ABC score showed the highest accuracy in predicting in-hospital mortality. The MAP(ASH) score was the most effective predictor of rebleeding and the need for interventions. Different scoring systems have been optimized for various clinical outcomes. The ABC score was the best for predicting mortality, whereas the MAP(ASH) score excelled in identifying rebleeding risks and intervention needs. The selection of an appropriate scoring tool based on specific clinical scenarios can improve patient management and resource allocation in NVUGIB.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to traumatology and orthopaedics, and can be used for surgical treatment of pyoinflammatory processes of bone and soft tissue structures of the patient's locomotor system. That is ensured by preoperative preoperative surgical treatment by standard X-ray imaging, fistulography and ultrasonic diagnostics of volume and border of pyoinflammatory process. Thereafter, an area of pyoinflammatory complications is accessed. Necrotically altered bone tissues are incised to support cortical layer with simultaneous removal of pathologically changed soft tissues. Flow-aspiration drainage of the formed cavity is ensured by antiseptic solutions. Then the bone cavity of the post-excision defect cleared from pathologically changed bone and soft-tissue structures is filled with a prepared soft spacer in form of macroporous cryogel based on polyvinyl alcohol with size of interconnected macropores from 2 to 10 mcm, made in the form of a set of spacers in the form of cubes, parallelograms, balls and irregular geometrical shape, impregnated as an antibacterial agent with aqueous solutions of tobramycin and/or dalbavancin with concentration of 10–50 mg/ml. Aqueous solution of the antibacterial preparation tobramycin in its mixture with an aqueous solution of dalbavancin is selected from 20 to 80 vol. %. Then the wound is closed in layers. In 40–60 days thereafter, the spacer is removed from the bone cavity of the post-excision defect.EFFECT: method provides reliable prevention of repeated occurrence of pyoinflammatory processes with simultaneous preservation of blood supply and innervation of tissues, reliable provision of bone defect filling with material with high antibacterial properties, ensuring the bone tissues and wound tissues closure with their own tissues, as well as reliable restoration of the anatomical, functional integrity and motor capabilities of the patient's extremity.1 cl, 5 ex
HIV is associated with NK cell dysfunction and expansion of adaptive-like NK cells that persist despite antiretroviral therapy (ART). We investigated the timing of NK cell perturbations during acute HIV infection and the impact of early ART initiation. PBMCs and plasma were obtained from people with HIV (PWH; all men who have sex with men; median age, 26.0 y) diagnosed during Fiebig stages I, II, III, or IV/V. Participants initiated ART a median of 3 d after diagnosis, and immunophenotyping was performed at diagnosis and longitudinally after ART. Anti-CMV Abs were assessed by ELISA. Samples from matched HIV-uninfected males were also analyzed. Proportions of adaptive NK cells (A-NKs; defined as Fcε-Receptor-1γ-) were expanded at HIV diagnosis at all Fiebig stages (pooled median 66% versus 25% for controls; p < 0.001) and were not altered by early ART initiation. Abs to CMV immediate early protein were elevated in PWH diagnosed in Fiebig stages III and IV/V (p < 0.03 for both). Proportions of A-NKs defined as either Fcε-Receptor-1γ- or NKG2C+/CD57+ were significantly associated with HIV DNA levels at diagnosis (p = 0.046 and 0.029, respectively) and trended toward an association after 48 wk of ART. Proportions of activated HLA-DR+/CD38+ NK cells remained elevated in PWH despite early ART initiation. NK cell activation and A-NK expansion occur very early after HIV transmission, before T cell activation, and are not altered by ART initiation during acute infection. A-NKs may contribute to HIV control and thus be useful for HIV cure.
INTRODUCTION: Hypertensive nephrosclerosis (HN) ranks as one of the most frequent causes of chronic kidney disease (CKD), but its very existence has repeatedly been called into question, especially in young adults. Its diagnostic framework is established chiefly on non-specific clinical criteria, and its defining histopathological set of features is in fact shared by numerous other conditions. Genetic testing based on exome sequencing (ES) has emerged as a comprehensive tool to detect Mendelian diseases in timely fashion in nephrology, with a significant number of re-established diagnoses. The aim of this study was to investigate the diagnostic yield of ES in patients with a clinical diagnosis of hypertensive nephropathy.
METHOD: Since September 2018, ES has been readily available as part of the routine diagnostic work-up in our institution. The indication of ES includes hypertensive nephropathy of early onset (i.e., <45 years old). We retrospectively collected the ES data performed in the context of hypertensive nephropathy in our institution between September 2018 and February 2021.
RESULTS: A total of 128 patients were sequenced in the context of hypertensive nephropathy with early onset. The chief indications of ES were an early onset of CKD (47%), family history of kidney disease (8%), or both (18%). We detected diagnostic variants in 19 of the 128 patients (15%), encompassing a total of 13 different monogenic disorders. The diagnostic yield of ES was lower in patients of African ancestry (diagnostic yield of 7 vs. 30% in non-African ancestry patients, p < 0.001).
CONCLUSIONS: The high diagnostic yield of ES (15%) in a population of patients thought to have HN casts further doubts on the validity of the existing diagnosis criteria, including histological criteria, supposed to characterize the condition. This was especially true in patients with no African ancestry, where ES positivity reached 30%.
JYNARQUE increases free water clearance and, as a result, may cause dehydration, hypovolemia and hypernatremia. Therefore, ensure abnormalities in sodium concentrations are corrected prior to initiation of therapy.

Instruct patients to drink water when thirsty, and throughout the day and night if awake. Monitor for weight loss, tachycardia and hypotension because they may signal dehydration.

In the two double-blind, placebo-controlled trials of patients with ADPKD, hypernatremia (defined as any serum sodium concentration >150 mEq/L) was observed in 4.0% versus 0.6% and 1.4% versus 0% of tolvaptan-treated versus placebo-treated patients, respectively. The rate of dehydration and hypovolemia in the two studies was 2.1% versus 0.7% and 2.3% versus 0.4% for tolvaptan-treated versus placebo-treated patients, respectively.

During JYNARQUE therapy, if serum sodium increases above normal range or the patient becomes hypovolemic or dehydrated and fluid intake cannot be increased, then suspend JYNARQUE until serum sodium, hydration status and volume status is within the normal range.
<P>PROBLEM TO BE SOLVED: To provide a therapeutic method for cancer by using an agonist and an antagonist of IL-23.  <P>SOLUTION: The method for treating tumors, especially for modulating activities of cytokine molecules and receptors of the same is provided. The IL-23 agonist or antagonist is able to modulate proliferation of the tumors. Cytokinin molecules of mammals and related reagents thereof are used. More precisely, cytokinin-like protein of the mammals which can be used for treating proliferation disorders and inhibiter thereof are identified.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Primary outcome is serum level of voriconazole on fifth day. Secondary outcome is a combined variable of therapeutic failure and adverse events, associated with voriconazole. A total of 146 patients with risk of undergoing invasive aspergillosis who potentially will receive voriconazole will be recruited, and CYP2C19 will be genotyped. If the patient receives voriconazole finally, he will be randomized (1:1 experimental/control). In the experimental arm patients receive dose according to pharmacogenetic algorithm including CYP2C19 genotype and clinical and demographic information. In the control arm patients receive dose according to clinical practice guidelines. In addition, a Spain national health system (NHS) point-of-view cost-effectiveness evaluation is going to be done. Direct costs calculation of each arm will be done.
The final stage of almost all chronic kidney diseases is renal fibrosis. Simple wounds or persistent inflammation can cause tissue inflammation, which, in the case of the kidney, results in scarring. Vascular sclerosis, tubulointerstitial fibrosis and glomerular fibrosis are all types of kidney fibrosis. Renal damage and fibrosis are caused by elevated expression of CXCR4. This study aimed to identify possible pharmacological agents which could bind to and inhibit isoform I of CXCR4 and determine their strength of interactions. The I-TASSER, Galaxyweb and Robetta were used to predict and refine the structure of the CXCR4 protein. ModBase was used to improve the loops, and then the quality was evaluated by using the ERRAT value (92.15) and Ramachandran plot. The improved 3D structure was subjected to small molecule database docking using Maestro (from Schrodinger) and the glide module. GROMACS was used to simulate molecules with the three top low glide scores and the best ADME properties. The best glide score was achieved by ligand ID 4990 (-11.5). Simulations, free energy landscape and residue decomposition analysis revealed that 4990 interacted more consistently with CXCR4 than the other two small molecules.Communicated by Ramaswamy H. Sarma.
Risperidone, widely used in the treatment of schizophrenia, has been shown to be effective in the treatment of manic and mixed episodes associated with bipolar disorders. Antipsychotic drugs like risperidone have also been used as additional therapeutic agents in the treatment of patients who are not responsive to mood stabilizers alone. This is a randomized, double-blind, placebo-controlled study to evaluate the effectiveness and safety of risperidone compared with placebo, as an addition to mood stabilizing drugs in the treatment of patients experiencing manic episodes. Treatment of one group of patients with haloperidol is used as an internal control in the trial. The study has two phases: a double-blind treatment phase (3 weeks) and an open-label phase (10 weeks). During the double-blind treatment phase patients receive risperidone, haloperidol, or placebo tablets to be taken once a day at gradually increasing doses (adjusted to 1 to 6 mg/day for risperidone and 2 to 12 mg/day for haloperidol), while continuing treatment with a mood stabilizer (lithium or valproate). In the open-label phase all patients receive risperidone with the dosage gradually adjusted to achieve optimal effectiveness (dose range of 0 to 6 mg/day); in this phase patients continue therapy with a mood stabilizer (lithium, valproate, or, for this phase only, carbamazepine). The primary measure of effectiveness is the change in the Young Mania Rating Scale (YMRS) total score from baseline to end of double-blind treatment. Additional assessments of effectiveness include the Brief Psychiatric Rating Scale (BPRS); the Clinical Global Impression (CGI), which evaluates the change in severity of the disorder; and the Hamilton Depression Rating Scale (HAMD). Safety assessments include the incidence of adverse events throughout the study; measurement of vital signs (pulse and blood pressure) and evaluation of the presence and severity of extrapyramidal symptoms by the Extrapyramidal Symptom Rating Scale (ESRS) at specified intervals; and clinical laboratory tests (hematology, biochemistry, urinalysis) before study initiation, at completion of double-blind treatment, and at the end of study. The study hypothesis is that daily treatment with risperidone as add-on therapy provides better effectiveness than placebo, as measured by Young Mania Rating Scale scores, in the treatment of the manic phase of bipolar disorder. Double-blind (daily doses, taken orally once a day) - Days 1 and 2: risperidone 2 mg, haloperidol 4 mg, or placebo. Days 3 and 4: risperidone 1 - 4 mg, haloperidol 2 - 8 mg, or placebo. Days 5 - 21: risperidone 1 - 6 mg, haloperidol 2 - 21 mg, or placebo. Open-label: risperidone 0 - 6 mg/day for 10 weeks.
Walnut oil for expelling wind and removing cold is prepared from the following raw materials, by weight, 250-260 parts of East China wild walnut, 30-40 parts of flaxseed, 70-80 parts of Zanthoxylum armatum DC., 50-60 parts of cocoanut shell, 60-120 parts of talcum, 40-70 parts of Radix Scutellariae, 50-80 parts of capillary wormwood, 30-50 parts of grass-leaved sweetflag rhizome, 20-40 parts of fritillaria cirrhosa, 20-40 parts of akebia stem, 20-40 parts of wrinkled giant hyssop, 20-40 parts of fructus forsythia, 20-40 parts of roud cardamon seed, 20-40 parts of mint, 20-40 parts of rhizoma belamcandae and the like. Zanthoxylum armatum DC. which is added during the preparation process has effects of expelling wind and removing cold; talcum has effects of clearing heat and draining dampness to relieve summer-heat; capillary wormwood has effects of clearing heat and draining dampness to remove jaundice; and Scutellaria baicalensis has effects of eliminating dampness and heat and purging fire for removing toxin. With compatibility of the three medicines, the effects of clearing heat and promoting diuresis are achieved, and advantages of two medicines are performed. Grass-leaved sweetflag rhizome and wrinkled giant hyssop have effects of repelling foulness, regulating the middle warmer and removing stagnation of turbid dampness. Cluster cardamom is fragrant and pleasant and has effects of removing qi stagnation and eliminating dampness. Akebia stem has effects of eliminating dampness and heat through urination. Fructus forsythia, fructus forsythia, fritillaria cirrhosa and mint have effects of relieving internal heat or fever, relieving sore-throat and removing stasis and swelling. With combination of the above medicines, effects of clearing heat and promoting dieresis are highlighted, and the effect of promoting circulation of qi with aromatics is also considered. The walnut oil provided by the invention can relieve internal heat or fever, relieve sore-throat and clear heat and expel dampness, and is suitable for patients with damp-heat syndromes such as rheumatism, fatigue, abnormal hair and the like.
BACKGROUND: The regenerative capacity of the adult mammalian hearts is limited. Numerous studies have explored mechanisms of adult cardiomyocyte cell-cycle withdrawal. This translational study evaluated the effects and underlying mechanism of rhCHK1 (recombinant human checkpoint kinase 1) on the survival and proliferation of cardiomyocyte and myocardial repair after ischemia/reperfusion injury in swine.
METHODS AND RESULTS: Intramyocardial injection of rhCHK1 protein (1 mg/kg) encapsulated in hydrogel stimulated cardiomyocyte proliferation and reduced cardiac inflammation response at 3 days after ischemia/reperfusion injury, improved cardiac function and attenuated ventricular remodeling, and reduced the infarct area at 28 days after ischemia/reperfusion injury. Mechanistically, multiomics sequencing analysis demonstrated enrichment of glycolysis and mTOR (mammalian target of rapamycin) pathways after rhCHK1 treatment. Co-Immunoprecipitation (Co-IP) experiments and protein docking prediction showed that CHK1 (checkpoint kinase 1) directly bound to and activated the Serine 37 (S37) and Tyrosine 105 (Y105) sites of PKM2 (pyruvate kinase isoform M2) to promote metabolic reprogramming. We further constructed plasmids that knocked out different CHK1 and PKM2 amino acid domains and transfected them into Human Embryonic Kidney 293T (HEK293T) cells for CO-IP experiments. Results showed that the 1-265 domain of CHK1 directly binds to the 157-400 amino acids of PKM2. Furthermore, hiPSC-CM (human iPS cell-derived cardiomyocyte) in vitro and in vivo experiments both demonstrated that CHK1 stimulated cardiomyocytes renewal and cardiac repair by activating PKM2 C-domain-mediated cardiac metabolic reprogramming.
CONCLUSIONS: This study demonstrates that the 1-265 amino acid domain of CHK1 binds to the 157-400 domain of PKM2 and activates PKM2-mediated metabolic reprogramming to promote cardiomyocyte proliferation and myocardial repair after ischemia/reperfusion injury in adult pigs.